Oncology Live®
Vol. 17/No. 24
Volume: 17
Issue: 24
Vol. 17/No. 23
Volume: 17
Issue: 23
Vol. 17/No. 22
Volume: 17
Issue: 22
Vol. 17/No. 21
Volume: 17
Issue: 21
Vol. 17/No. 20
Volume: 17
Issue: 20
Vol. 17/No. 19
Volume: 17
Issue: 19
Vol. 17/No. 18
Volume: 17
Issue: 18
Vol. 17/No. 17
Volume: 17
Issue: 17
Vol. 17/No. 16
Volume: 17
Issue: 16
Vol. 17/No. 15
Volume: 17
Issue: 15
Vol. 17/No. 14
Volume: 17
Issue: 14
Vol. 17/No. 13
Volume: 17
Issue: 13
Vol. 17/No. 11
Volume: 17
Issue: 11
Vol. 17/No. 9
Volume: 17
Issue: 9
Vol. 17/No. 10
Volume: 17
Issue: 10
Vol. 17/No. 7
Volume: 17
Issue: 7
Vol. 17/No. 8
Volume: 17
Issue: 5
Vol. 17/No. 12
Volume: Vol-17-No-
Issue: 12
Vol. 17/No. 5
Volume: 17
Issue: 5
Vol. 17/No. 4
Volume: 17
Issue: 4
Vol. 17/No. 3
Volume: 17
Issue: 3
Vol. 17/No. 2
Volume: 17
Issue: 2
Vol. 17/No. 1
Volume: 17
Issue: 1
Vol. 17/No. 6
Volume: 17
Issue: 6
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5